A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: The preclinical AD consortium

Alden L. Grossa, Jason J. Hassenstab, Sterling C. Johnson, Lindsay R. Clark, Susan M. Resnick, Melissa Kitner-Triolo, Colin L. Masters, Paul Maruff, John C. Morris, Anja Soldan, Corinne Pettigrew, Marilyn S. Alberth: 2017 Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring Volume 8, Pages 147-155 Read More


Introduction We established a method for diagnostic harmonization across multiple studies of preclinical Alzheimer’s disease and validated the method by examining its relationship with clinical status and cognition. Methods Cognitive and clinical data were used from five studies (N = 1746). Consensus diagnoses established in each study used criteria to identify progressors from normal cognition to mild cognitive impairment. Correspondence was evaluated between these consensus diagnoses and three algorithmic classifications based on (1) objective cognitive impairment in 2+ tests only; (2) a Clinical Dementia Rating (CDR) of ≥0.5 only; and (3) both. Associations between baseline cognitive performance and cognitive change were each tested in relation to progression to algorithm-based classifications. Results In each study, an algorithmic classification based on both cognitive testing cutoff scores and a CDR ≥0.5 provided optimal balance of sensitivity and specificity (areas under the curve: 0.85–0.95). Over an average 6.6 years of follow-up (up to 28 years), N = 186 initially cognitively normal participants aged on average 64 years at baseline progressed (incidence rate: 15.3 people/1000 person-years). Baseline cognitive scores and cognitive change were associated with future diagnostic status using this algorithmic classification. Discussion Both cognitive tests and CDR ratings can be combined across multiple studies to obtain a reliable algorithmic classification with high specificity and sensitivity. This approach may be applicable to large cohort studies and to clinical trials focused on preclinical Alzheimer’s disease because it provides an alternative to implementation of a time-consuming adjudication panel. © 2017 The Authors

Full Text


Posted on July 14, 2017
Posted in: HPAN, Neurodegeneration, Publications Authors: